Skip to content

Human microdosing for the prediction of patient response

Paul T. Henderson, C. Pan

Bioanalysis March 1, 2010 DOI: 10.4155/bio.10.3 (opens in new tab)

Read Full Text
Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Topics Microdosing
Key findings Argues that microdosing, originally developed in molecular toxicology, is now being applied to medical diagnostics, with recent efforts focusing on prognostic and predictive diagnostics to improve disease detection and treatment.

Abstract

Microdosing allows study of the behavior of drugs via the administration of doses so low they are unlikely to produce whole-body effects, but of sufficient concentration to allow the determination of absorption, distribution, metabolism and excretion (ADME). Microdosing was recently reviewed elsewhere [1,2]; although most effort to date has focused on pharmacokinetic (PK) predictions to accelerate drug development, microdosing was born out of molecular toxicology research [3-10] and is now extending to medical diagnostics applications. Here, we provide a brief overview of microdosing for drug development, followed by a description of recent efforts to implement prognostic and predictive diagnostics aimed at improving detection and treatment of human disease.

Comparable studies

Other narrative reviews on microdosing, most cited first.

Study Year Design Participants
Big physics, small doses: the use of AMS and PET in human microdosing of development drugs 2003 Review
Phase 0/microdosing approaches: time for mainstream application in drug development? 2020 Review
Microdosing and drug development: past, present and future 2013 Review
Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development 2016 Review
Expectancy Effects in Psychedelic Trials. 2024 Review

Citations in the library

Cited by 3

Related reading

Explore topics

Microdosing